Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Crane Company

Griffon

Players in the Zacks Diversified Operations industry are leveraging the pandemic-induced demand in the medical equipment and personal safety products markets. Also, strengthening businesses in markets like defense and industrial manufacturing are boons.

4 Worthy Stocks From Flourishing Diversified Operations Industry

Danaher Corporation (DHR) CEO Rainer Blair on Q4 2020 Results - Earnings Call Transcript

Danaher's (DHR) Q4 results reflect strength in Diagnostics, Life Sciences, and Environmental & Applied Solutions segments as well as growth in margins. Core sales growth projections are impressive.

Danaher (DHR) Q4 Earnings Beat Estimates, Sales View Solid

Danaher (DHR) delivered earnings and revenue surprises of 13.04% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Q4 Earnings and Revenues Surpass Estimates

WASHINGTON, Jan. 28, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2020. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended December 31, 2020, net...

Danaher Reports Fourth Quarter And Full Year 2020 Results

Dover

Hilltop Holdings

National Instruments

Olin

PulteGroup

Six stocks are set to beat fourth-quarter earnings estimates tomorrow. These are: DHR, DOV, OLN, PHM, HTH, NATI.

Top 6 Stocks Poised to Beat on Q4 Earnings Tomorrow

Abbott Labs

Johnson Controls

ServiceNow

Stanley Black & Decker

It's not easy to beat every quarter on earnings for five years, including during a global pandemic. These companies have done it.

5 Incredible Perfect Earnings Charts

Danaher (DHR) Q4 results to reflect benefits from solid Diagnostics and Life Sciences demand. Also, positive impacts of acquired assets and foreign currency translations are likely to have aided.

Will Danaher (DHR) Keep Its Earnings Streak Alive in Q4?

The Danaher Corporation uses a continuous improvement strategy called the Danaher Business System. After starting as a Lean Manufacturing practice, it evolved and expanded into a system that affects every aspect of the company's operations and business.

How Danaher Created An Enduring Competitive Advantage

Danaher Corporation (DHR) CEO Rainer Blair Presents at J.P. Morgan Healthcare Conference Call Transcript

Broadcom

Alphabet

NVIDIA

QUALCOMM

Block

Tesla

We have narrowed down our search to seven corporate behemoths that have strong growth potential in 2021. These are: TSLA, SQ, NVDA, FB, AVGO, DHR and QCOM.

7 Top Corporate Behemoths With Immense Upside Left in 2021

WASHINGTON, Jan. 7, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2020 on Thursday, January 28, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying...

Danaher Schedules Fourth Quarter 2020 Earnings Conference Call

Deere & Company

FedEx

General Motors

Micron Technology

We have selected eight stocks that have strong strong potential for 2021 and beyond. These are: DE, MU, GM, TSLA, FDX, NVDA, DHR and GOOGL.

Wall Street Defeats Pandemic: Bulls Set to Roar in 2021

Algonquin Power & Utilities

American Water Works

Invesco S&P Global Water Index ETF

First Trust Water ETF

Miller/Howard High Income Equity Fund

Invesco Water Resources ETF

Invesco Global Water ETF

Xylem

Water doesn't typically get the same focus that I put on other utilities like electric and gas companies. Though, that doesn't mean that investing in water ETFs doesn't have its own merits; it certainly does as global demand rises, yet supply doesn't go up.

ETFs: 5 Funds For Investing In Water, A Vital Resource

WASHINGTON, Dec. 21, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that Jose-Carlos ("JC") Gutierrez-Ramos has been named Senior Vice President and Chief Scientific Officer for Danaher. In this role, Dr. Gutierrez-Ramos will have responsibility for helping define...

Danaher Announces Executive Appointment

Microsoft

We have narrowed down our search to five corporate behemoths that have popped more than 30% year to date. These are: NVDA, DHR, UPS, MSFT and AVGO.

5 Must-Buy Corporate Giants as Major Indexes Hit Record High

Illinois Tool Works

Roper Technologies

Three well-run companies and what investors can take away from their outperformance in the past decade.

Why Management Matters: The 3 Best-Run Industrial Companies in America

Evercore

Danaher Corporation (DHR) CEO Rainer Blair Presents at Evercore ISI 3rd Annual HealthCONx Brokers Conference (Transcript)

Coty

Foot Locker

Biglari Hlds

Biohaven Pharmaceutical Hld

Stoke Therapeutics Inc

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was before and after the elections and as the pandemic worsens.

Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And More

Science and technology company Danaher Corporation (NYSE: DHR) boasts a high-quality and defensive portfolio that has become "less compelling to own" ahead of a cyclical recovery into 2021, according to RBC Capital Markets. The Analyst: Deane Dray downgraded Danaher from Outperform to Sector Perform with a price target lowered from $273 to $234.

RBC Downgrades Danaher, Says Defensive Portfolio 'Less Compelling To Own'

Target

Thermo Fisher Scientific

It will be prudent to invest in large-cap stocks with a favorable Zacks Rank that are members of any of the three large-cap indexes. These are DHR, UPS, NVDA, MSFT, TGT, TMO, DE, FDX.

Enjoy Thanksgiving with a Wall Street Bonanza

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Danaher (DHR) Down 3.5% Since Last Earnings Report: Can It Rebound?

WASHINGTON, Nov. 16, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Wolfe Research Healthcare Conference on Thursday, November 19, 2020 at 12:00 p.m. ET. The audio will be...

Danaher To Present At Wolfe Research Healthcare Conference

Estee Lauder

Johnson & Johnson

Coca-Cola

McDonald's

Mondelez

PepsiCo

Procter & Gamble

Walmart

In this article we present the list of Top 10 Stocks Billionaire Ray Dalio Just Bought. Click to skip ahead and see the  Top 5 Stocks Billionaire Ray Dalio Just Bought .

Top 10 Stocks Billionaire Ray Dalio Just Bought

Danaher (DHR) to benefit from healthy growth opportunities in Life Sciences and Diagnostics segments, acquired assets and shareholders-friendly policies.

News for Danaher Stock (DHR)